KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib is a paper indexed in ScholarIQ from OpenAlex.
How many citations does KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib have?
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib has 1,526 citations in the OpenAlex counts ScholarIQ stores.
When was KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib published?
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib has 2005 year in the ScholarIQ index.
What is the open-access status of KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib?
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib has gold oa status in the ScholarIQ index.
What is the DOI of KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib?
The DOI for KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib is on the source record.
What is the PMID of KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib?
The PMID for KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib is on the source record.
What is the OpenAlex record for KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib?
The OpenAlex for KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib is on the source record.